Accessing Genetic Information with Liquid Biopsies
Xinjiang Cai,Filip Janků,Qimin Zhan,Jie Fan
DOI: https://doi.org/10.1016/j.tig.2015.06.001
IF: 11.4
2015-01-01
Trends in Genetics
Abstract:Recent scientific advances in understanding circulating tumor cells, cell-free DNA/RNA, and exosomes in blood have laid a solid foundation for the development of routine molecular ‘liquid biopsies’. This approach provides non-invasive access to genetic information – somatic mutations, epigenetic changes, and differential expression – about the physiological conditions of our body and diseases. It opens a valuable avenue for future genetic studies and human disease diagnosis, including prenatal and neurodegenerative disease diagnosis, as well as for cancer screening and monitoring. With the rapid development of highly sensitive and accurate technologies such as next-generation sequencing, molecular ‘liquid biopsies’ will quickly become a central piece in the future of precision medicine. Recent scientific advances in understanding circulating tumor cells, cell-free DNA/RNA, and exosomes in blood have laid a solid foundation for the development of routine molecular ‘liquid biopsies’. This approach provides non-invasive access to genetic information – somatic mutations, epigenetic changes, and differential expression – about the physiological conditions of our body and diseases. It opens a valuable avenue for future genetic studies and human disease diagnosis, including prenatal and neurodegenerative disease diagnosis, as well as for cancer screening and monitoring. With the rapid development of highly sensitive and accurate technologies such as next-generation sequencing, molecular ‘liquid biopsies’ will quickly become a central piece in the future of precision medicine. There will be huge efforts from both academia and industry to develop ultrasensitive and specific methods, including technology platforms, assays, and data analysis tools for (i) circulating cell isolation, manipulation and characterization/analysis, and (ii) circulating nucleic acids analysis. There will be large-scale, well-designed clinical trials to demonstrate the clinical utility of ctDNA/CTC for disease detection and monitoring. There will be continued efforts to integrate knowledge from liquid biopsies into our understanding of health and disease conditions. Non-invasive, liquid biopsy-based diagnostics will be rapidly incorporated into standard healthcare practice and become the central piece in the future precision medicine. There will be huge efforts from both academia and industry to develop ultrasensitive and specific methods, including technology platforms, assays, and data analysis tools for (i) circulating cell isolation, manipulation and characterization/analysis, and (ii) circulating nucleic acids analysis. There will be large-scale, well-designed clinical trials to demonstrate the clinical utility of ctDNA/CTC for disease detection and monitoring. There will be continued efforts to integrate knowledge from liquid biopsies into our understanding of health and disease conditions. Non-invasive, liquid biopsy-based diagnostics will be rapidly incorporated into standard healthcare practice and become the central piece in the future precision medicine. in vitro diagnostics that provide information essential for the safe and effective use of a corresponding drug or biological product, such as cancer-targeted therapy drugs. in eukaryotic genomes, regions of several hundred bp that are enriched with CpG dinucleotides. They often overlap with transcription start-sites and can regulate gene expression via their differential methylation states [67Laird P.W. Principles and challenges of genome-wide DNA methylation analysis.Nat. Rev. Genet. 2010; 11: 191-203Crossref PubMed Scopus (1227) Google Scholar]. addition of a methyl group to cytosine residues at the carbon 5 position (5meC) [67Laird P.W. Principles and challenges of genome-wide DNA methylation analysis.Nat. Rev. Genet. 2010; 11: 191-203Crossref PubMed Scopus (1227) Google Scholar]. first discovered in 2008, exosomes are plasma membrane bounded nanovesicles secreted into the extracellular environment from endosomes, and contain cytoplasmic contents such as mRNA, miRNA, and proteins [28Properzi F. et al.Exosomes: the future of biomarkers in medicine.Biomark. Med. 2013; 7: 769-778Crossref PubMed Scopus (299) Google Scholar]. the presence of a small number of malignant cells after treatment. as opposed to the automated Sanger method, which is considered a first-generation technology, NGS allows parallel analysis of thousands to many millions of sequencing reactions; therefore, it is also known as massively parallel sequencing (MPS) [68van Dijk E.L. et al.Ten years of next-generation sequencing technology.Trends Genet. 2014; 30: 418-426Abstract Full Text Full Text PDF PubMed Scopus (978) Google Scholar]. Unlike conventional prenatal molecular cytogenetics, which involves invasive procedures, NIPT is a non-invasive approach for detection of fetal chromosomal disorders, such as Down, Edwards, and Patau syndromes, that rely on analysis of cell-free DNA in maternal blood. method to sequence only the coding regions (exons) of a genome [68van Dijk E.L. et al.Ten years of next-generation sequencing technology.Trends Genet. 2014; 30: 418-426Abstract Full Text Full Text PDF PubMed Scopus (978) Google Scholar]. method for robust amplification of an entire genome, starting with picogram quantities of DNA (as low as a single cell) and resulting in nanogram or microgram quantities of DNA for subsequent genetic analysis. Commonly used WGA methods include multiple displacement amplification (MDA), degenerate-oligonucleotide-primed PCR (DOP-PCR), and multiple annealing and looping-based amplification cycles (MALBAC). method to sequence all bases of a genome, including both coding and non-coding regions.